Associations - CDK12 mutation

CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A2 - Guideline	olaparib Sensitive: A2 - Guideline
CDK12 mutation CDK12 mutation	Ovarian Cancer Ovarian Cancer	CDK12 mutation CDK12 mutation	Ovarian Cancer Ovarian Cancer	olaparib Sensitive: B - Late Trials	olaparib Sensitive: B - Late Trials
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	nivolumab Sensitive: C2 – Inclusion Criteria	nivolumab Sensitive: C2 – Inclusion Criteria
CDK12 mutation CDK12 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CDK12 mutation CDK12 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	durvalumab Sensitive: C2 – Inclusion Criteria	durvalumab Sensitive: C2 – Inclusion Criteria
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	AST-2970 Resistant: C3 – Early Trials	AST-2970 Resistant: C3 – Early Trials
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	enzalutamide Resistant: C3 – Early Trials	enzalutamide Resistant: C3 – Early Trials
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	rucaparib Resistant: C3 – Early Trials	rucaparib Resistant: C3 – Early Trials
CDK12 mutation CDK12 mutation	Breast Cancer Breast Cancer	CDK12 mutation CDK12 mutation	Breast Cancer Breast Cancer	olaparib Sensitive: C3 – Early Trials	olaparib Sensitive: C3 – Early Trials
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	GnRH stimulant Resistant: C3 – Early Trials	GnRH stimulant Resistant: C3 – Early Trials
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	enzalutamide + abiraterone acetate Resistant: C3 – Early Trials	enzalutamide + abiraterone acetate Resistant: C3 – Early Trials
CDK12 mutation CDK12 mutation	Non Small Cell Lung Cancer NSCLC	CDK12 mutation CDK12 mutation	Non Small Cell Lung Cancer NSCLC	olaparib Sensitive: C4 – Case Studies	olaparib Sensitive: C4 – Case Studies
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	nivolumab + ipilimumab Sensitive: C4 – Case Studies	nivolumab + ipilimumab Sensitive: C4 – Case Studies